Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
120.50
+3.00 (2.55%)
At close: Apr 28, 2026
87.11%
Market Cap 6.19B
Revenue (ttm) 7.78M
Net Income (ttm) -165.97M
Shares Out 51.39M
EPS (ttm) -3.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 183,237
Average Volume 318,503
Open 117.50
Previous Close 117.50
Day's Range 115.50 - 120.50
52-Week Range 45.60 - 208.50
Beta -40.99
RSI 48.90
Earnings Date Apr 30, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia. The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid an... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.